Table 2.
Treatment initiation and breast cancer-specific mortality among incident invasive breast cancer cases for whom therapy was indicated by the National Comprehensive Cancer Network (NCCN) guidelines. Restricted to women who survived 12 or more months or 24 or more months.
| Received Treatment Indicated |
Subcohort (Weighted 6.67x) | Cases (Deaths ≥ 12 mo) | Survival HRa,b (≥12 mo post dx) | Survival HRa,b (≥ 24 mo post dx) | ||
|---|---|---|---|---|---|---|
| N | % | N | % | HR (95% CI) | HR (95% CI) | |
| Chemotherapy | ||||||
| Yes | 263 | 82.2 | 269 | 87.3 | 1.0 | 1.0 |
| No | 57 | 17.8 | 39 | 12.7 | 1.5 (0.8–2.7) | 1.3 (0.7–2.3) |
| Not indicated | 451 | 141 | ||||
| Radiation | ||||||
| Yes | 397 | 90.6 | 232 | 80.0 | 1.0 | 1.0 |
| No | 41 | 9.4 | 58 | 20.0 | 2.3 (1.2–4.4) | 2.1 (1.1–4.2) |
| Not indicated | 333 | 159 | ||||
| Endocrine Therapy | ||||||
| Yes | 278 | 86.6 | 172 | 81.1 | 1.0 | 1.0 |
| No | 43 | 13.4 | 40 | 18.9 | 2.0 (1.0–4.0) | 1.8 (0.9–3.7) |
| Not indicated | 450 | 237 | ||||
a
Adjusted for age, tumor size (National Comprehensive Cancer Network (NCCN) guideline categories < 1 cm, 1–<3 cm, 3–<5 cm, and ≥5 cm, chest wall/skin) positive lymph nodes (0, 1–3, 4+), tumor grade (1, 2, 3/4), estrogen receptor status, progesterone receptor status, Her2 status, and Hispanic ethnicity.
b
Abbreviations: HR – hazard ratio, CI – confidence interval